Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity
Objective The present study was undertaken to obtain data using the combination of SSc and lamivudine (LAM), entecavir (ETV) or telbivudine (LdT) in HepG2.2.15 cells to explore whether SSc acts as a potent adjuvant of nucleoside analogues in anti-HBV treatment. Methods HepG2.2.15 cells were incubated with either SSc combined with any one of three nucleoside analogues (NAs) LAM, ETV, LdT or only one of them for 48 h. The expression profiles of HBV DNA, HBsAg, HBeAg, and HBcAg were examined by real-time quantitative PCR, ELISA, and western blot. Results Compared with mono-drug treatment, the combination of SSc and any of the three nucleoside analogues significantly promoted additional reduction on HBV DNA level. Declined levels of HBsAg, HBeAg, and HBcAg were observed in SSc and LdT combination group. Conclusion These in vitro results indicated that SSc acted as a promising nucleoside analogue adjuvant, especially for telbivudine in the therapeutic strategies against HBV infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Inflammation research - 69(2020), 6 vom: 20. Apr., Seite 545-547 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Xiaohe [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s00011-020-01336-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR039616010 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR039616010 | ||
| 003 | DE-627 | ||
| 005 | 20230519135820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00011-020-01336-y |2 doi | |
| 035 | |a (DE-627)SPR039616010 | ||
| 035 | |a (SPR)s00011-020-01336-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Li, Xiaohe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective The present study was undertaken to obtain data using the combination of SSc and lamivudine (LAM), entecavir (ETV) or telbivudine (LdT) in HepG2.2.15 cells to explore whether SSc acts as a potent adjuvant of nucleoside analogues in anti-HBV treatment. Methods HepG2.2.15 cells were incubated with either SSc combined with any one of three nucleoside analogues (NAs) LAM, ETV, LdT or only one of them for 48 h. The expression profiles of HBV DNA, HBsAg, HBeAg, and HBcAg were examined by real-time quantitative PCR, ELISA, and western blot. Results Compared with mono-drug treatment, the combination of SSc and any of the three nucleoside analogues significantly promoted additional reduction on HBV DNA level. Declined levels of HBsAg, HBeAg, and HBcAg were observed in SSc and LdT combination group. Conclusion These in vitro results indicated that SSc acted as a promising nucleoside analogue adjuvant, especially for telbivudine in the therapeutic strategies against HBV infection. | ||
| 650 | 4 | |a Saikosaponin c |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Telbivudine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug combination |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ke, Zhiyi |e verfasserin |4 aut | |
| 700 | 1 | |a Lian, Dongli |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Yanchao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation research |d Cham : Springer International Publishing AG, 1969 |g 69(2020), 6 vom: 20. Apr., Seite 545-547 |w (DE-627)SPR000002968 |w (DE-600)1459194-7 |x 1420-908X |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2020 |g number:6 |g day:20 |g month:04 |g pages:545-547 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00011-020-01336-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |q ASE |
| 951 | |a AR | ||
| 952 | |d 69 |j 2020 |e 6 |b 20 |c 04 |h 545-547 | ||